GSK's new CEO, LabCorp's Covance leadership change and more.

Lundbeck has chalked up another Phase III failure for the Alzheimer's field. Neither dose hit the primary endpoint or showed separation from placebo.

AC Immune is offloading 6 million IPO shares, 32% more than originally planned, at the bottom end of its targeted $11 to $13 price range.

Daniel Soland has quit as CEO of uniQure "due to personal family reasons" 9 months after taking the job.

Teva has posted positive Phase III data for its involuntary twitch candidate deutetrabenazine as its gears up for a 2016 FDA filing--putting it a few months…

In our EuroBiotech roundup this week, Evotec lands a €300 million Bayer deal, Amgen teams with Genenta on cancer gene therapies, Faron raises money and more.

Gilead said in a brief update that it will be canning its combined Phase II/III test of its experimental GI med GS-5745 after finding that there was “…

Billionaire husband-and-wife team Priscilla Chan, a trained pediatrician, and Facebook founder Mark Zuckerberg will invest around $3 billion over the next 10…

iOmx Therapeutics has raised €40 million ($44.6 million) in a Series A round to get to proof-of-concept data.